Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Jay WarnerArtisan Partners Small Cap Fund | Ascendis Pharma A/S $ASND• NASDAQ | BiotechnologyBiotechnology | Artisan Partners Small Cap Fund - ASND Ascendis Pharma is a biotechnology company leveraging its proprietary TransCon platform to develop differentiated therapies for patients with significant unmet medical needs. Recent results were... | NEUTRAL | View Pitch → |
| Aug 21, 2026 | Fund Letter | Spyglass Capital | Ascendis Pharma A/S $ASND• NASDAQ | BiotechnologyBiotechnology | Long ASND (Ascendis Pharma A/S) The manager re-entered Ascendis Pharma following the incredibly successful US commercial launch of Yorvipath for hypoparathyroidism. Yorvipath enjoys monopoly... | BULL | View Pitch → |
| Nov 28, 2025 | Fund Letter | Jason WhiteArtisan Global Discovery | Ascendis Pharma A/S $ASND• NASDAQ | BiotechnologyBiotechnology | Artisan Global Discovery 2025 Q3 (ASND) Ascendis is a biotech company leveraging its proprietary TransCon™ platform to develop differentiated therapies that address unmet medical needs. This technology enables... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.